Bottom line is that INCY addresses only criteria, improvement in constitutional symptoms.

FORBES: Two-Minute Take: The Case For Exelixis And Incyte

One stock that Gibbons is particularly bearish on is Incyte (nasdaq: INCY - news - people), the first gene database company and one of Celera's rivals.

FORBES: Magazine Article

Among the largest underlying components of XBI, in trading today Pharmacyclics, Inc. ( NASD: PCYC) is up about 0.9%, Isis Pharmaceuticals, Inc. ( NASD: ISIS) is up about 3.6%, and Incyte Corporation ( NASD: INCY) is up by about 0.3%.

FORBES: XBI, PCYC, ISIS, INCY: Large Outflows Detected at ETF

Among the largest underlying components of XBI, in trading today Dendreon Corp ( NASD: DNDN) is up about 3.5%, Regeneron Pharmaceuticals, Inc. ( NASD: REGN) is up about 0.5%, and Incyte Corporation ( NASD: INCY) is higher by about 0.9%.

FORBES: XBI, DNDN, REGN, INCY: ETF Inflow Alert

Among the largest underlying components of XBI, in trading today Seattle Genetics Inc ( NASD: SGEN) is up about 0.4%, Incyte Corporation ( NASD: INCY) is up about 0.8%, and Pharmacyclics, Inc. ( NASD: PCYC) is up by about 1%.

FORBES: Noteworthy ETF Outflows: XBI, SGEN, INCY, PCYC

Many genomics companies such as Celera (nyse: CRA - news - people), Incyte (nasdaq: INCY - news - people) and Affymetrix (nasdaq: AFFX - news - people) make their money by helping larger drugmakers identify genes involved in disease.

FORBES: Genomics Won't Mean Cheap Drugs